Shine Technologies activated its accelerator-driven D-T neutron source at the Janesville production facility, reaching steady-state operation for medical-isotope production. The platform is the engineering precursor to Shine's planned commercial fusion-based isotope and waste-recycling lines.

While not a power-producing fusion device, Shine's approach is widely viewed as the most commercially mature fusion-adjacent business model in the sector, with revenue contracts from major radiopharmaceutical buyers signed through 2030.